NCT01737502View on ClinicalTrials.gov

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 14, 2014

Primary Completion Date

April 24, 2023

Study Completion Date

April 24, 2023

Conditions
Extensive Stage Small Cell Lung CarcinomaLung AdenocarcinomaRecurrent Non-Small Cell Lung CarcinomaRecurrent Small Cell Lung CarcinomaSquamous Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
Interventions
DRUG

Auranofin

Given PO

DRUG

Sirolimus

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (2)

32224

Mayo Clinic, Jacksonville

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER